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Abstract  
Introduction: Metastasis to the eye is a rare clinical entity accounting for about 2-9% ocular malignancies. Clinical 
awareness can lead to prompt diagnosis and appropriate management. 
Case presentation: We here present a case of a 60-year-old patient who visited to several ophthalmologists with the 
complaint of blurry vision in his left eye. He was diagnosed with anterior uveitis and elevated intraocular pressure. A 
masquerade syndrome was suspected, and anterior chamber paracentesis was performed, which revealed metastatic 
non-small cell lung cancer (NSCLC). CT chest revealed a left lung mass with right paratracheal lymphadenopathy. No 
other evidence of metastatic disease was found on PET/CT scan and MRI of the brain. He received treatment for stage IV 
lung cancer with carboplatin, paclitaxel, and bevacizumab. The intraocular tumor cell infiltration was treated with 
intravitreal bevacizumab that resulted in subjective and objective improvement. 
Conclusion: Metastasis to the eye may present in a masquerade-like fashion as intraocular inflammation. Tumor specific 
therapy directed locally within the eye may be a component of an overall treatment plan. 
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Introduction  
Metastasis to the eye though rare is the most common of all intraocular malignancies [1]. Out of these 
around 47–81% have breast cancer as the primary malignancy and 23% have lung cancer as the 
primary malignancy [1]. Further lung cancer is the most common cause of secondary intraocular 
malignancy in men, whereas breast cancer is the most common cause in women [2]. The choroid is the 
most common site for metastasis, whereas involvement of the ciliary body, retina, optic disc, vitreous 
and iris are rare. We discuss a patient who was diagnosed with metastatic NSCL (adenocarcinoma) 
after presenting with anterior uveitis and elevated intraocular pressure.  
Case presentation  
A 60 year old male active smoker with no significant past medical history presented with complains of 
redness and decreased vision in his left eye. Multiple optometrists and ophthalmologists had diagnosed 
him with anterior uveitis. His ophthalmological exam revealed his left eye (OS) visual acuity to be at 
20/25 with an intraocular pressure of 46mmHg. Anterior segment exam revealed cellular precipitates, 
1+ circulating cell, inferior anterior chamber debris, and engorged angle vessels on gonioscopy. The 
fundus exam was unremarkable. Metastatic infiltration of the iris and anterior chamber angle with 
secondary inflammation was suspected. Anterior chamber paracentesis was performed and histological 
exam showed metastatic NSCLC (Fig A and B). Post diagnosis his CXR showed a left sided mass. 
Remaining physical exam was normal. Laboratory studies including complete blood count and blood 
chemistry were within normal limits. Imaging studies including CT chest, abdomen and pelvis were 
significant only for heterogeneously enhancing mass in the left posterior medial lobe of lung 
measuring 9.4 cm by 7.8 cm along with a 1.1 cm right lower paratracheal lymph node. PET scan 
revealed a small focus of increased uptake SUV 3.5 along the medial aspect of left eye globe, without 
a discrete identifiable lesion on corresponding CT scan alongside a FGD avid left lung mass (SUV 
8.1) and mediastinal lymphadenopathy (SUV 3.4). Left lung CT guided biopsy confirmed the mass to 
be adenocarcinoma with signet ring cell morphology. EGFR, ALK mutations were tested negative but 
K-ras mutation was positive. 
He was diagnosed with stage IV NSCLC, T2a N2 M1b and was enrolled in a clinical trial for the 
treatment of his metastatic NSCLC; he received a total of four cycles of intensive chemotherapy with 
paclitaxel, carboplatin and bevacizumab. Patient achieved stable disease and was thereafter started on 
maintenance regimen with bevacizumab and pemetrexed. He was diagnosed two years ago and 
currently his disease is stable on maintenance treatment. 
He received one dose of intraocular bevacizumab injection (1.25 mg) prior to initiation of systemic 
chemotherapy. Within 2 weeks post intravitreal bevacizumab administration, the patient’s intraocular 
inflammation and pressure improved.  
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Fig. A Picture of the anterior chamber of the eye showing cellular precipitates without any iris nodules or 
lesions. 
 
 
 
Fig. B Histopathology of the anterior chamber fluid showing cellular debris and malignant cells consistent with 
adenocarcinoma of the lung. 
  
 
Ivy Union Publishing | http: //www.ivyunion.org April 21, 2016 | Volume 4, Issue 1 
Iqbal M et al. American Journal of Cancer Case Reports 2016, 4:19-24 
6 
Page 4 of 6 
 
Fig. C CT chest with contrast demonstrating left lower lung mass. 
Discussion 
The incidence of ocular metastasis from lung cancer is reported to be 2-7% [1]. Choroid is the most 
commonly involved site followed by iris and the ciliary body [2, 8]. Patients presenting with this kind 
of lesion are usually in the late stages of their primary disease [9]. The vascularity of the uveal tract is 
thought to predispose it to metastasis though no clear etiology has been postulated
 
[3]. These lesions 
can present either posteriorly as posterior segment lesions, or anteriorly as anterior uveitis as seen in 
our patient; other presentations include iris nodules, and neovascularization of the iris [10]. With 
regards to the iris, metastasis is usually unilateral whereas bilateral choroid involvement is sometimes 
seen. Further iris metastasis tends to involve the irido-corneal angle with resultant secondary glaucoma 
[12]. 
Shields et al reported that, in 56% of patients with intraocular lung cancer metastasis, the diagnosis 
of the primary tumor was made afterwards, highlighting the importance of early recognition of 
intraocular metastasis [4].
 
However it was estimated in a study by Kreusel et al that in patients with 
metastatic lung carcinoma, just 7.1% presented with ocular involvement [15]. 
The symptomology can range from blurry vision, photopsia, red eye, floaters and visual field defects 
[9]. 
The diagnosis of ocular metastasis is based primarily on clinical findings supported by imaging 
studies. The various diagnostic procedures include ultrasonography, fluorescein angiography, 
computed tomography/MRI and fine needle aspiration [2]. 
There are various treatment modalities available for the treatment for intraocular metastasis, 
including systemic chemotherapy, radiotherapy and lately progress has been made in molecular 
targeted therapies. In general ocular metastasis respond favorably to systemic chemotherapy; however, 
local therapy is warranted when there is enlargement of the lesion, pain or visual disturbance [1, 13]. 
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With increasing knowledge of the oncogenes involved in the pathogenesis of NSCLC, targeted 
therapies are now proving to provide greater therapeutic advantages. EGFR, k-RAS and ALK are the 
oncogenes most commonly associated with NSCLC. All of these mutations are more commonly found 
in adenocarcinoma and are involved in cellular survival and neoplastic proliferation [1, 7]. 
Solid tumor growth and metastasis is dependent on neovascularization. Thus the use of molecular 
targets of therapy that inhibit angiogenesis halts tumor growth. VEGF and EGFR are such targets 
[8].
 
Bevacizumab is an anti VEGF monoclonal antibody that has shown promising results [11, 13].
 
It 
inhibits endothelial cells from responding to angiogenic protein VEGF. This is the underlying principle 
with regards to its use in tumors expressing high levels of VEGF. When used via intraocular injections 
it inhibits neo-vascularization and eventually tumor growth. Reports have been cited of patients 
presenting with choroid mass that underwent complete regression along with subjective and objective 
improvement after the use of intravitreal bevacizumab [5, 6, 8]
.
 Further erlotinib, a reversible, orally 
available, highly selective epidermal growth factor receptor tyrosine kinase inhibitor, has also 
demonstrated encouraging results in the treatment of intraocular NSCLC metastasis [8, 13]
.
 Maturu et 
al in their systemic review talk about 9 cases that received intravitreal bevacizumab primarily due to 
choroid metastases, with improved vision and regression of metastases in 6 out of 9 patients further 
supporting the use of molecular targets of therapy
 
[16]
.
 
With combined local and systemic therapy, patient achieved reduction in intraocular inflammation 
and improved intraocular pressure. 
Conclusion 
Intraocular metastasis is a potential masquerade and should be considered in the differential diagnosis 
of uveitis. Intravitreal bevacizumab is a promising molecular target of therapy that inhibits 
neovascularization and tumor growth with resultant clinical benefits in patients presenting with 
intraocular metastasis. 
Consent  
Patient’s consent was taken prior to submission for peer review. 
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